Global Psoriasis Treatment Market To Rise At A CAGR Of 5.10% Between 2016 - 2024 and Reach US$12.1 Bn By 2024

Researchmoz added Most up-to-date research on "Global Psoriasis Treatment Market To Rise At A CAGR Of 5.10% Between 2016 - 2024 and Reach US$12.1 Bn By 2024" to its huge collection of research reports.

This report on the Psoriasis Treatment market analyzes the current and future scenario of the global market. Approval of new biologics, increase in access for the treatment in developing market, increase in the number of psoriasis patients, are boosting the growth of the global Psoriasis Treatment market. Increase in the incidence of Psoriasis and skin disorders, and novel pipeline drugs are some of the factors expected to drive the growth of global Psoriasis Treatment market during the forecast period.

The Psoriasis Treatment market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on products, distribution channel, therapy type and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section.

Additionally, the section comprises Porter’s Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Psoriasis Treatment market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=931750

Global Psoriasis Treatment Market - Segmentation

In this report, the market segments have been analyzed based on availability of approved products, cost-effectiveness, and preference for technological systems by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on product type, the market has been segmented into TNF Inhibitors, Vitamin D analogues or its combination, Interleukin Blockers and Others. Interleukin blockers segment is likely to be the most attractive segment in the near future due to its increasing use and its ability to act selectively by targeting the proteins. The segment is expected to grow at a highest CAGR rate during forecast period.

Based on Therapy type, the global Psoriasis Treatment market has been segmented into Topical Therapeutic Drugs, Systemic Therapeutic Drugs, Combinations of therapies & others. The market segments have been extensively analyzed based on increase in demand for the therapies, availability of the drug products, and cost of therapy and severity of the disease.

Browse TOC @ https://www.researchmoz.us/psoriasis-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2016-2024-report.html/toc

Different types of distribution channels are responsible for making the psoriasis treatment available in the market. The distribution channels are Hospital pharmacy, Retail pharmacy and the online sales. Under the distribution channel segment, hospital pharmacy plays a major role followed by retail pharmacy and online sales.

Geographically, the global Psoriasis Treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Saudi Arabia, and Rest of Middle East & Africa).

Companies Mentioned in the Report

The report also profiles major players in the global Psoriasis Treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Amgen Inc., Eli Lilly and Company, Novartis AG, Merck & Co., Inc., Johnson & Johnson, Pfizer, Inc., AstraZeneca, AbbVie Inc., LEO Pharma A/S and Biogen.

The Global Psoriasis Treatment Market has been segmented as given below:

Psoriasis Treatment Market, by Product

• TNF Inhibitors
• Vitamin D Analogues or Combinations
• Interleukin Blockers
• Others 

Psoriasis Treatment Market, by Therapy

• Topical Therapeutic Drugs
• Systemic Therapeutic Drugs
• Combinations
• Others

Psoriasis Treatment Market, by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales
• Others

Psoriasis Treatment Market, by Region

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• India
• China
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Asia-Pacific Systemic Psoriasis Therapeutics Market to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

Researchmoz added Most up-to-date research on "Asia-Pacific Systemic Psoriasis Therapeutics Market to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth" to its huge collection of research reports.

GBI Research, the leading business intelligence provider, has released its latest research: ‘Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth’, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.

In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $435m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $773m. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant market share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.

Scope

The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=286550

The report includes:

• A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms
• In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy
• A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target
• Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type
• Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets
• Discussion of the drivers of and barriers to market growth
• In-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006

Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

• Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative
• Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
• Follow the trends in psoriasis clinical trial size and duration in relation to industry averages
• Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates
• Analyze the potential growth patterns expected for the psoriasis market over the forecast period
• Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers
• Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Browse More Details @ http://www.researchmoz.us/systemic-psoriasis-therapeutics-in-asia-pacific-markets-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-report.html

LATAM Adalimumab Global Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2023

Researchmoz added Most up-to-date research on "LATAM Adalimumab Global Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2023" to its huge collection of research reports.

This report on LATAM Adalimumab market analyzes the current and future prospects of the adalimumab sales pertaining to Latin American countries. The stakeholders of this report include companies engaged in production and commercialization of adalimumab biosimilars across the globe. This report encompasses an elaborate executive summary, with a market snapshot that provides overall information of major market segments and sub-segments included in the study scope. This section also provides the overall information and data analysis of the LATAM Adalimumab market with respect to the leading market segments based on, application and major Latin American countries. 

The LATAM Adalimumab market has been segmented on the basis of application, and Latin American countries. The application segment has been further segmented into rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis and others. The LATAM adalimumab country segment has been further categorized into Brazil, Mexico, Argentina, Colombia and Rest of LATAM. The market for each of these segment has been analyzed on the basis of adalimumab prescription for various disorders and regulatory scenario with respect to biologic drugs in respective countries. Market revenue in terms of US$ Mn for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all the segments, considering 2014 as the base year. 

The market overview section of this report explores market dynamics such as drivers, restraints, and opportunities that have predominant impact on the LATAM adalimumab market presently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to elucidate the intensity of competition in the market in different LATAM countries. Furthermore, pipeline analysis of the adalimumab biosimilar molecules in Phase III stage have been provided in market overview section. The market estimations for pipeline molecules are provided assuming the positive entry of these molecules in the market which will have an impact on the sustainability of the companies operating in this market. All these factors would help the market players to take strategic decisions in order to strengthen their positions and expand their shares in the LATAM market. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=582355

The LATAM adalimumab analysis with respect to major LATAM countries provides the landscape for the production and marketing of adalimumab biosimilars with the introduction of favorable reimbursement policies, research expertise which paves a path for the local and foreign investments in these countries. The report also profiles major players in the adalimumab market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the major players profiled in this report include AbbVie, Inc., Amgen, Inc., Mylan N.V., Novartis AG, Pfizer, Inc. and others. 

The LATAM Adalimumab market is segmented into the following categories:

• LATAM Adalimumab Market, by Application
  • Rheumatoid Arthritis
  • Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Others
• LATAM Adalimumab Market, by Country
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=582355